Kane Biotech (CVE:KNE) Trading Down 12.5% – Should You Sell?

Shares of Kane Biotech Inc. (CVE:KNE) were down 12.5% on Monday . The company traded as low as C$0.04 and last traded at C$0.04. Approximately 138,000 shares changed hands during trading, a decline of 23% from the average daily volume of 180,043 shares. The stock had previously closed at C$0.04.

Kane Biotech Stock Performance

The firm has a fifty day simple moving average of C$0.04 and a 200 day simple moving average of C$0.04. The company has a current ratio of 0.90, a quick ratio of 0.39 and a debt-to-equity ratio of -289.57. The stock has a market cap of C$6.69 million, a price-to-earnings ratio of -0.50 and a beta of 0.43.

Kane Biotech Company Profile

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.